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INTRODUCTION
Preeclampsia is a contributor to maternal as well
as perinatal morbidity and mortality, with rate of
preeclampsia in all pregnancy estimated to be
5%.1,2 Although the etiology of preeclampsia is
definitely unclear, it is suspected that the presence
of endothelial dysfunction plays an important role
in the development of preeclampsia.2-4 Preeclamp-
sia is a clinical diagnosis, with the classic definition
of preeclampsia consisting of three components;
hypertension (blood pressure >140/90 mmHg in
women who previously had normal blood pres-
sure); proteinuria (>300mg/24 hours or +2 on uri-
nalysis examination in the absence of urinary tract
infection); and edema. However, a recent consen-
sus excluded edema as a criterion for diagnosing
preeclampsia. So far, screening tests and preven-
tion of preeclampsia have not been available. Com-
plications resulting from preeclampsia include
eclampsia, hemolysis, elevated liver enzymes, low
platelets (HELLP syndrome), disseminated intra-
Abstract
Objective: To identify and analyze the differences in the levels of
PlGF in preeclampsia and normal pregnancy.
Method: This was a cross-sectional observational qualitative study
of PlGF in preeclampsia and normal pregnancy. The number of sam-
ples in case and control group was 30 in each groups.
Result: We found that mean of maternal age in the preeclampsia
group was 28.53 years and 25.23 years in the control group. Mean
parity in preeclampsia and control group was 2.33 and 1.56, respec-
tively. Mean hemoglobin level in preeclampsia and control group
was 11.97 and 11.99, respectively. Mean maternal blood glucose
level was 87.0 in the preeclampsia group, and 87.9 in the control
group. In the preeclampsia group mean urea concentration was
16.45, while it was 22.78 in the control group. Mean creatinine level
was 0.92 in the preeclampsia group and 0.64 in the control group.
Mean SGPT and SGOT in the preeclampsia group was 23.36 and
21.97, while in the control group was 29.86 and 26.20. Test results
showed that PlGF levels was significantly different between the pree-
clampsia and control group. Mean PlGF in the preeclampsia and con-
trol group was 42.10 and 452.33 respectively, with p <0.001.
Conclusion: We can conclude that the level of PlGF in the pree-
clampsia group is lower than the normal pregnancy group.
[Indones J Obstet Gynecol 2015; 2: 76-80]
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Abstrak
Tujuan: Mengetahui dan menganalisis perbedaan kadar PlGF pada
preeklampsia dan kehamilan normal.
Metode: Penelitian ini adalah penelitian kuantitatif observasional
menggunakan pendekatan potong lintang kadar PlGF pada preek-
lampsia dan kehamilan normal. Jumlah sampel pada masing-masing
kelompok kasus dan kontrol adalah 30 orang.
Hasil: Dari hasil penelitian kami, didapatkan bahwa rerata variabel
umur ibu hamil pada kelompok preeklampsia adalah 28,53 tahun, se-
dangkan pada kelompok kontrol adalah 25,23 tahun. Rerata paritas un-
tuk kelompok preeklampsia dan kontrol adalah 2,33 dan 1,56. Rerata
kadar hemoglobin adalah 11,97 untuk kelompok preeklampsia dan
11,99 untuk kelompok kontrol. Untuk rerata GDS ibu pada kelompok
preeklampsia 87,0, kelompok kontrol adalah 87,9. Pada kelompok preek-
lampsia didapatkan rerata ureum sebesar 16,45 dan 22,78 untuk kontrol.
Rerata kreatinin 0,92 untuk preeklampsia dan 0,64 untuk kelompok kon-
trol. Pada rerata SGPT dan SGOT pada kelompok preeklampsia 23,36
dan 21,97, sedangkan pada kelompok kontrol sebesar 29,86 dan 26,20.
Hasil pemeriksaan kadar PIGF menunjukkan bahwa terdapat perbedaan
signifikan antara kelompok preeklampsia dan kelompok kontrol. Pada
kelompok preeklampsia didapatkan rerata PlGF sebesar 42,10 dan
452.33 untuk kontrol dengan p<0,001.
Kesimpulan: Berdasarkan analisis hasil penelitian didapatkan kesim-
pulan bahwa kadar PlGF pada kelompok preeklampsia lebih rendah
daripada kelompok dengan kehamilan normal.
[Maj Obstet Ginekol Indones 2015; 2: 76-80]
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vascular coagulophaty (DIC), hypertensive emer-
gency, hypertensive encephalopathy and blindness
in cortical regions.4,5
In the United States, preeclampsia 23.6 cases oc-
curs in every 1000 delivery.6,7 The incidence of
preeclampsia in Indonesia was 3-10% and ac-
counted for 39.5% of maternal mortality in 2001
and increased to 55.56% in 2002.8
Although preeclampsia has been studied exten-
sively for numerous decades, the etiology and pa-
thogenesis of this disease remains unclear. Cur-
rently many theories trying to explain the etiology
and pathogenesis of preeclampsia exist, including
genetic predisposition, thrombophilia, endocrino-
pathy, vasculopathy, placental ischemia, oxidative
stress, and immune maladaptation.9,10
Preeclampsia is mostly believed to occur in two
stages. The first stage is the preclinical stage, which
is a process of endothelial disruption and inade-
quate cytotrophoblast invasion of the spiral arte-
ries in the myometrium. This poor placentation
process leads to ischemia and hypoxia in the pla-
centa. The second stage occurs in late pregnancy,
where the presence of placental oxidative stress
causes the release of anti-angiogenic proteins such
as soluble Fms-like Tyrosine Kinase-1 (sFlt-1), pros-
taglandins and cytokines into the maternal circula-
tion. On the other hand, the state of oxidative stress
will suppress the production of pro-angiogenic fac-
tors, including placental growth factor (PlGF) and
vascular endothelial growth factor (VEGF).11
There was growing evidence about the imba-
lance between angiogenic factors, such as PlGF and
VEGF, with angiogenesis inhibiting factors, such as
sFlt-1 and soluble Endoglin (zinc), in the patho-
genesis of preeclampsia. sFlt-1 was found to be
responsible for the syndrome of preeclampsia. In a
study of animals given exogenous sFlt-1, symptoms
of preeclampsia such as hypertension, proteinuria
and kidney damage was shown. sFlt-1 is increased
in preeclampsia, and decreased to normal levels af-
ter birth. In contrast with sFlt-1, PlGF concentra-
tions decreases in preeclampsia.12 Levine et al re-
ported that the increase of sFlt-1 as a result of en-
dothelial dysfunction caused a decrease of free
PlGF in serum preeclampsia.13 Soluble Fms-like Ty-
rosine Kinase-1 is an antagonist of PlGF and VEGF,
are bound and prevents the interaction of PlGF and
VEGF in endothelial surface receptors.14,15
The balance between PlGF, VEGF (pro-angio-
genic factors) and sFlt-1 (anti-angiogenic factors)
is important in the process of angiogenesis, vascu-
logenesis and placental development during preg-
nancy.16
PlGF is a member of the VEGF polypeptide fa-
mily. In recent times, it has been observed that se-
rum PlGF level at mid-pregnancy is significantly
lower in obese women. It has been established that
PlGF could be an effective predictor of preeclamp-
sia in the early second trimester of pregnancy.
However, some researchers also considered PlGF
to be more effective as a biomarker in high-risk
populations although the predictive value of these
biomarkers appear to be limited in early onset pre-
eclampsia.17,18 Based on this, the researchers in-
tend to conduct a study to determine and analyze
the differences in the levels of PlGF in preeclampsia
and normal pregnancy.
METHODS
We carried out a cross-sectional observational qua-
litative study of PlGF in preeclampsia and normal
pregnancy. This study was conducted in the De-
partment of Obstetrics and Gynecology, RSUP Prof.
Dr. RD Kandou from September to October 2013.
Patients with preeclampsia and normal preg-
nancy presenting in the outpatient unit who meet
the inclusion criteria and provided informed con-
sent after receiving explanation about the proce-
dure of this study. Inclusion criteria include women
with preeclampsia or normal pregnancy, at term,
gave birth in RSUP Prof. Dr. RD Kandou, Manado,
and willing to participate in this study. Women
having chronic diseases such as diabetes mellitus,
cardiovascular or kidney abnormality, chronic hy-
pertension, multiple pregnancy, IUFD, premature
rupture of fetal membranes, intrauterine infection,
congenital malformation, or placental abnormali-
ties (hemangiomatous placenta or placenta previa)
were excluded from this study. The sample size
needed to meet 90% power of this study was 30
subjects in each preeclampsia and control group.
About 10 ml of blood sample was taken from the
cubital vein, 5 ml for PlGF serum assay and 5 ml
for blood sugar, SGOT, SGPT, ureum, creatinine, he-
moglobin, leukocyte and total protein test. The
blood tests, except for PlGF assay, were done in
RSUP Prof. Dr. RD Kandou laboratory. Blood for
PlGF assay was centrifuged at 2000-3000 rpm for
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15 minutes and then stored in the freezer with a
temperature of -20°C before it was sent to Prodia
Laboratory in Jakarta in an ice pack to maintain the
temperature. PlGF was tested quanitatively using
ELISA.
Serum PlGF data from the preeclampsia and con-
trol group was collected and compared statistically
using t-test. Data analysis was done using SPSS 17.0
for Windows.
RESULTS
The subjects of this study were 60 pregnant wo-
men at term that met the inclusion criteria. They
were allocated into 2 groups, preeclampsia as the
case group and normal pregnancy as the control
group. Baseline characteristics of our subjects are
shown in Table 1.
From this study, we found that the mean mater-
nal age in the preeclampsia group was 28.53 years,
and 25.23 years in the control group. The mean
parity in preeclampsia and control group was 2.33
and 1.56, respectively. Mean hemoglobin and ma-
ternal blood glucose was similar in both groups.
Moreover, in the preeclampsia group mean urea
level was 16.45, while it was 22.78 in the control
group. Mean creatinine was 0.92 in the preeclamp-
sia group and 0.64 in the control group. Mean SGPT
and SGOT in the case group was 23.36 and 21.97,
while it was 29.86 and 26.20 in the control group.
Table 1. Baseline Characteristics
Characteristics
Control Group Preeclampsia
Total (n) Percentage (%) Total (n) Percentage (%)
Age
<20 years 14 56.67 14 56.67
20-24 years 3 10.0 3 10.0
25-29 years 5 16.67 5 16.67
30-35 years 8 26.67 8 26.67
Weight
<60 kg 7 23.3 7 23.3
60-79 kg 20 66.6 20 66.6
80-100 kg 3 10.0 3 10.0
>100 kg - - - -
Education level
High school 2 6.67 2 6.67
Junior high school 5 16.67 5 16.67
Senior high school 19 63.33 19 63.33
College 4 13.33 4 13.33
Occupation
Housewive 14 56.67 14 56.67
Civil servant 6 20.0 6 20.0
Private company 10 33.33 10 33.33
Ethnic group
Minahasa 20 66.6 20 66.6
Sangihe 4 13.33 4 13.33
Gorontalo 4 13.33 4 13.33
Javanese 2 6.67 2 6.67
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Table 2. Distribution of Study Variables
Variables Group N Mean
Age (yo) Preeclampsia 30 28.5
Control 30 25.2
Parity Preeclampsia 30 2
Control 30 2
Hb (gr/dl) Preeclampsia 30 11.9
Control 30 11.9
Blood glucose (mg/ dl) Preeclampsia 30 89
Control 30 87
Ureum (mg/ dl) Preeclampsia 30 16.4
Control 30 22.7
Creatinin (mg/dl) Preeclampsia 30 0.9
Control 30 0.6
SGOT (U/l) Preeclampsia 30 23.3
Control 30 21.9
SGPT (U/l) Preeclampsia 30 29.8
Control 30 26.2
Serum PIGF level from preeclampsia and con-
trol group was collected and compared statistically
using SPSS 17.0 for Windows. Mean PlGF in pre-
eclampsia and control group was 42.10 and 452.33,
respectively. Statistical analysis showed that PlGF
levels in the preeclampsia and control group was
significantly different. Using Mann-Whitney test we
found that the difference of PIGF level between the
control and preeclampsia group was statistically
significant (p<0.01).
DISCUSSION
Preeclampsia is a complication of pregnancy pre-
senting in the form of a syndrome with serious con-
sequences for the mother and fetus. Incidence of
preeclampsia was found to be 7% to 10%. This
syndrome is characterized by the presence hyper-
tension, proteinuria and multi-organ failure. Pre-
eclampsia is considered as a multi-system syn-
drome, characterized by vasoconstriction, metabo-
lic changes, endothelial dysfunction, activation of
the coagulation cascade, and increased inflamma-
tory response.1
Although preeclampsia has been studied exten-
sively for several decades, the etiology and patho-
genesis of this disease is still unclear. Angiogenesis
is one of the important processes that play a role
in the development of the vascular system of the
placenta. Among several angiogenic factors, VEGF
and PlGF play an important role in the vascular sys-
tem of the placenta. It has been proven that an im-
balance between angiogenesis factors such as VEGF
and PlGF and antagonist of angiogenesis factors,
such as sFlt-1, plays a major role in the pathogene-
sis of preeclampsia. Angiogenic factors PlGF and
VEGF have an essential function for placental de-
velopment and the effectiveness of endothelial
cells.9,10
In normal pregnancy, serum PlGF concentration
increases at 8-12 weeks gestation, peaks at 29-32
weeks gestation, and then declines at 33-40 weeks
gestation.11 In several studies, PlGF showed low
levels in preeclampsia. PlGF levels in women who
develop preeclampsia was found to be significantly
lower than in normotensive pregnancies at 13-16
weeks gestation until the beginning of labor. In ad-
dition it was also reported that at the beginning of
the second trimester (10 or 11 weeks), levels of
PlGF in pregnancies that would evolve into pre-
eclampsia was lower compared to normal preg-
nancy.11,16
PlGF has been proposed as a marker and me-
diator of endothelial dysfunction in preeclampsia.
Some studies found that the concentration of PlGF
in preeclampsia is 3 to 10 times lower than in nor-
mal pregnancy. PlGF concentration in preeclampsia
begins to fall at 9-11 weeks before the onset of hy-
pertension and proteinuria; or at least 5 weeks be-
fore the onset of this condition.16
Many studies have evaluated the levels of PlGF
in preeclampsia compared with normotensive
pregnancies. Krauss et al reported that out of all
pregnancies with preeclampsia, 27.3% had PlGF
levels below 200 pg/ml.19 Bersinger et al found le-
vels of PlGF in preeclampsia to be significantly
lower than in normotensive pregnancy at term.20
Likewise, Shen et al found levels of PlGF in preg-
nancies with preeclampsia to be significantly lower
compared to normotensive pregnancies at the
same gestational age.
This study is an observational study using quan-
titative cross-sectional approach to prove the exist-
ence of differences in the angiogenic factor (PlGF)
in normal pregnancies and pregnancies with pree-
clampsia.
We found that the difference between mean le-
vels of PlGF between the preeclampsia group and
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normotensive group was significant (p<0.05),
where levels of PlGF in the preeclampsia group was
42.10 pg/dl, and in the normotensive group was
452.33 pg/dl.
There are several explanations regarding the de-
creased levels of PlGF in pregnancies with pre-
eclampsia. First, low levels of PlGF occur due to in-
adequate trophoblast proliferation into the mater-
nal spiral arteries in early pregnancy. It may occur
due to impaired renal function, capillary thicken-
ing, decreased perfusion and other mechanism.
Looking at the results of this study and some pre-
vious studies, we can conclude that PlGF is very
potential to be developed as a predictor of pre-
eclampsia. By evaluating the PlGF levels in preg-
nant women as early as possible, we can predict
the occurrence of preeclampsia and possibly pre-
vent it.
Although the results of this study showed a sig-
nificant difference between preeclampsia with nor-
motensive pregnancies, this research has some li-
mitations including the limited number of samples,
so we could not determine the cut-off point of the
occurrence of preeclampsia. Moreover, the study
was limited to proangiogenic factor levels (PlGF) in
term pregnancy. Research on early gestation until
term is needed to allow us to clearly see the differ-
ence in the levels of angiogenic factors in normal
pregnancies and pregnancies with preeclampsia.
Furthermore, PlGF concentration is influenced by
many factors, such as the presence of ischemic tis-
sue, malignancy, inflammation and multiple other
abnormalities. Therefore, changes in PlGF concen-
tration are not only specific to preeclampsia.
CONCLUSION
Based on our study results, we can conclude that
the level of PlGF in pregnancy complicated by pree-
clampsia is lower than in normal pregnancy. A mul-
ticenter study involving more participants who
were observed from the beginning of pregnancy
until delivery is needed in order to apply the re-
sults on the population of pregnant women in pre-
venting preeclampsia.
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